 3. Subjects must have histologically or cytologically confirmed solid tumor malignancy that is unresectablelocally advanced andor metastatic and for which standard curative or palliative measures are not available or are no longer effective for all subjects, histologic or cytologic proof of malignancy based on prior primary cancer pathology is acceptable. 